查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016888

轉染試劑及設備市場：全球市場按產品類型、細胞類型、應用和最終用戶分類的預測，2026-2032年

Transfection Reagents & Equipment Market by Product Type, Cell Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，轉染試劑和設備市場價值將達到 14.9 億美元，到 2026 年將成長到 16 億美元，到 2032 年將達到 24.3 億美元，複合年成長率為 7.18%。

主要市場統計數據
基準年 2025 14.9億美元
預計年份：2026年 16億美元
預測年份 2032 24.3億美元
複合年成長率 (%) 7.18%

轉染試劑和儀器的市場正經歷著快速的技術和商業性變革，這主要得益於遞送化學、自動化技術的進步以及基因調控研究範圍的不斷擴大。近年來，研究人員和採購團隊已將採購重點從成本驅動型轉向可重複性、擴充性和法規可追溯性。因此，供應商正大力投資於平台穩定性、檢驗的實驗方案以及整合的軟硬體解決方案，以減少不同細胞類型和實驗形式之間的差異。

本導言概述了報告的主題，重點在於創新、營運韌性和終端用戶需求。導言也強調了分子生物學家、工程師和生物資訊學家之間跨學科合作對產品開發週期日益成長的影響。此外，導言指出，生物製藥公司對支持加速轉化工作流程（例如細胞株開發和基因治療研究）的試劑和儀器的需求不斷成長。透過將這些趨勢置於更廣泛的研究重點和採購慣例背景下，本導言建立了貫穿整個報告的分析框架，並表明了報告旨在提供可操作的見解以支持戰略決策的預期目標。

變革性的變化正在重新定義轉染工作流程，包括自動化、非病毒遞送技術的創新、單細胞方法以及與基因編輯平台的整合。

轉染生態系統正經歷一場變革性的轉變，這場變革正在重塑從實驗室到臨床的工作流程。首先，轉染工作流程的自動化和小型化降低了人為操作的差異性，實現了高通量實驗，並加速了方案最佳化的迭代週期。其次，非病毒遞送技術的創新，包括新一代脂質體、聚合物和物理方法，正在拓寬適用細胞類型和有效載荷的範圍，從而使以往因毒性或效率低下而受限的應用成為可能。

評估美國於 2025 年徵收的關稅對生命科學實驗室整個供應鏈、籌資策略和業務永續營運的累積影響。

2025年關稅的實施為整個轉染價值鏈的採購、供應商關係和成本結構帶來了一系列營運和策略壓力。為因應這一局面，許多實驗室和機構立即調整了籌資策略，以緩解短期成本上漲，優先選擇製造地多元化且能夠提供本地庫存緩衝的供應商。這些調整通常涉及重新談判條款、合併訂單以維持價格，以及加強與經銷商的合作以確保供應的連續性。

透過對產品類型、電池類型、應用和最終用戶進行關鍵細分分析，揭示了細微的需求促進因素和採購行為。

基於細分市場的洞察揭示了每種產品類型、細胞類型、應用和最終用戶的不同需求模式和操作要求。根據產品類型，市場細分為儀器和試劑兩部分。儀器的採購越來越受到與自動化系統相容性和數據整合的影響，而試劑的評估則側重於配方穩定性和跨平台性能。根據細胞類型，市場被細分為細菌細胞、昆蟲細胞、哺乳動物細胞和植物細胞。每種細胞類型都有獨特的轉染靈敏度、通量要求和驗證挑戰，這些都會影響試劑的選擇和方案的開發。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和競爭地位，為市場進入和夥伴關係策略提供了寶貴的見解。

區域趨勢影響關鍵區域的競爭定位和打入市場策略。在美洲，生物製藥研發投入的增加，以及合約研究組織 (CRO) 和先進學術研究中心的強大實力，推動了對高性能試劑和整合儀器的需求，這些試劑和儀器能夠支援轉化醫學流程。該地區的市場參與企業通常優先考慮監管合規性、供應商透明度和能夠加速臨床應用的夥伴關係模式。

透過研發、夥伴關係和平台擴展，對推動轉染試劑和儀器市場發展的主要企業進行策略概況和能力分析。

該領域的主要企業正透過整合研發投入、策略夥伴關係以及拓展平台功能來脫穎而出。一些企業專注於對試劑進行化學最佳化，以提高遞送效率並降低細胞毒性，即使在難治性細胞類型中也是如此；而另一些企業則致力於整合硬體、軟體和耗材，提供降低應用門檻的承包解決方案。試劑開發商與儀器製造商之間的合作日益普遍，與學術研究機構和受託研究機構(CRO) 的合作也越來越多，旨在檢驗不同應用情境下的工作流程。

為產業領導者提供實用建議，以加速採用、最佳化供應鏈，並在不同的轉染市場區隔領域中取得價值。

產業領導者應採取一系列切實可行的措施，加速技術應用，強化供應鏈，並在各個細分市場中獲取策略價值。首先，應投資開發檢驗的跨平台方案和全面的應用說明，以展示技術在關鍵細胞類型和應用場景中的表現。這些依證將降低技術應用門檻，並為學術機構、生物製藥公司和合約研究組織 (CRO) 的採購決策提供支援。其次，應實現生產和物流地點的多元化，以降低貿易和關稅風險，同時確保關鍵試劑和設備組件的持續供應。

調查方法詳細介紹了資料來源、與相關人員的訪談、一手和二手研究的整合以及確保嚴謹性的分析框架。

本分析的調查方法透過整合一手訪談、二手資料整合和交叉檢驗的專家評審，確保了分析的嚴謹性和有效性。一手研究包括對頂尖學術機構、生物製藥公司和合約研究組織（CRO）的實驗室主任、採購經理、研發科學家和業務部門負責人進行結構化訪談。透過這些對話，我們直接了解了採購因素、績效挑戰和驗證重點。

總結了相關人員在轉染生態系統中所面臨的策略意義、風險考量和優先行動。

總之，轉染試劑和儀器的生態系統正在創新、監管預期和採購行為變化交匯融合，並不斷發展演變。遞送化學、自動化以及與基因編輯平台整合的技術進步，在擴大應用範圍的同時，也提高了可重複性和品質保證的標準。同時，貿易趨勢和不斷發展的區域能力正在重塑供應鏈策略和商業性模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：轉染試劑與設備市場：依產品類型分類

  • 裝置
  • 試劑

第9章：轉染試劑與設備市場：依細胞類型分類

  • 細菌細胞
  • 昆蟲細胞
  • 哺乳動物細胞
  • 植物細胞

第10章：轉染試劑與設備市場：依應用領域分類

  • 細胞株構建
  • 藥物發現
  • 基因治療研究

第11章 轉染試劑與設備市場：依最終用戶分類

  • 學術研究機構
  • 生物製藥公司
  • 合約研究機構

第12章 轉染試劑與設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 轉染試劑與設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 轉染試劑與設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國轉染試劑與設備市場

第16章：中國轉染試劑與設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Altogen Biosystems
  • Applied Biological Materials, Inc.
  • Bex Co.,ltd.
  • BioVision Inc.
  • Bio-Rad Laboratories, Inc.
  • Cytiva
  • GeneCopoeia, Inc.
  • Lonza Group AG
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-031685195779

The Transfection Reagents & Equipment Market was valued at USD 1.49 billion in 2025 and is projected to grow to USD 1.60 billion in 2026, with a CAGR of 7.18%, reaching USD 2.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.49 billion
Estimated Year [2026] USD 1.60 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 7.18%

The transfection reagents and equipment landscape is experiencing rapid technological and commercial evolution, driven by converging advances in delivery chemistry, automation, and the expanding scope of gene-modulation research. Over the past several years, researchers and procurement teams have shifted priorities from cost-centric purchasing to an emphasis on reproducibility, scalability, and regulatory traceability. As a result, suppliers are investing heavily in platform robustness, validated protocols, and integrated hardware-software solutions that reduce variability across cell types and experimental formats.

This introduction frames the report's thematic focus on innovation, operational resilience, and end-user needs. It highlights how product development cycles are increasingly informed by cross-disciplinary collaboration between molecular biologists, engineers, and bioinformaticians. In addition, it acknowledges the heightened expectations from biopharmaceutical companies for reagents and instruments that support accelerated translational workflows, including cell line development and gene therapy research. By situating these trends within the broader context of research priorities and procurement practices, the introduction establishes the analytic lens used throughout the report and sets expectations for actionable insights that support strategic decision-making.

Transformative shifts redefining transfection workflows including automation, non-viral delivery innovations, single-cell approaches, and convergence with gene editing platforms

The transfection ecosystem is undergoing transformative shifts that are reshaping workflows from bench to clinic. First, automation and miniaturization of transfection workflows have reduced manual variability and enabled higher-throughput experimentation, which supports more rapid iterative cycles in protocol optimization. Second, non-viral delivery innovations, including next-generation lipids, polymers, and physical methods, are broadening the range of tractable cell types and payloads, enabling applications that were previously constrained by toxicity or low efficiency.

Concurrently, the widespread adoption of gene editing platforms such as CRISPR-Cas systems has created tighter integration between delivery reagents and editing toolkits, leading to bundled solutions that improve editing efficiency and reduce off-target effects. Single-cell analysis and high-content screening are also influencing reagent formulation and instrument design, requiring gentler delivery approaches and highly reproducible conditions. Moreover, regulatory and quality expectations are driving demand for reagents and equipment with robust documentation, lot-to-lot consistency, and compatibility with GMP workflows. Together, these shifts compel suppliers and end users to rethink product road maps, validation strategies, and service models to remain competitive and to accelerate translational impact.

Cumulative impact assessment of United States tariffs introduced in 2025 on supply chains, procurement strategies, and operational resilience across life science labs

The imposition of tariffs in 2025 introduced a set of operational and strategic pressures that have affected procurement, supplier relationships, and cost structures across the transfection value chain. In the immediate aftermath, many laboratories and organizations revisited sourcing strategies to mitigate near-term cost increases, prioritizing suppliers with diversified manufacturing footprints or those able to offer localized inventory buffers. These adjustments often involved renegotiating terms, consolidating orders to preserve pricing, and working more closely with distributors to maintain continuity of supply.

Over a longer horizon, tariffs have accelerated conversations about onshoring critical production and increasing supplier redundancy. Firms with the operational agility to reallocate production or to shift component sourcing have been better positioned to protect experimental continuity. At the same time, smaller academic and research institutions have faced more acute budgetary pressure, prompting procurement teams to seek multi-use reagents and instrumentation that deliver broader utility across projects. Importantly, tariffs have magnified the strategic importance of supply chain transparency and supplier risk assessment, encouraging organizations to invest in vendor qualification and inventory planning to sustain R&D pipelines under evolving trade conditions.

Key segmentation insights across product types, cell types, applications, and end users revealing nuanced demand drivers and procurement behaviors

Segmentation-driven insights reveal differentiated demand patterns and operational requirements across product types, cell types, applications, and end users. Based on Product Type, the market is studied across Equipment and Reagents, with equipment purchases increasingly influenced by compatibility with automation systems and data integration, while reagents are evaluated for formulation stability and cross-platform performance. Based on Cell Type, the market is studied across Bacterial Cells, Insect Cells, Mammalian Cells, and Plant Cells, and each category exhibits distinct transfection sensitivities, throughput needs, and validation challenges that influence reagent selection and protocol development.

Based on Application, the market is studied across Cell Line Development, Drug Discovery, and Gene Therapy Research, with cell line development demanding reproducibility and scale-up pathways, drug discovery emphasizing throughput and assay compatibility, and gene therapy research prioritizing delivery efficiency and regulatory-grade documentation. Based on End User, the market is studied across Academic And Research Institutes, Biopharmaceutical Companies, and Contract Research Organizations, where academic labs often prioritize flexibility and cost-effectiveness, biopharma focuses on qualification and portability to clinical pipelines, and CROs require broad reagent and equipment portfolios to service diverse client needs. Collectively, these segmentation perspectives underscore the importance of tailored value propositions, validated workflows, and service models that address the specific technical and commercial drivers inherent to each category.

Regional dynamics and competitive positioning across the Americas, Europe Middle East & Africa, and Asia-Pacific informing market entry and partnership strategies

Regional dynamics are shaping competitive positioning and go-to-market strategies across major geographies. In the Americas, investment in biopharmaceutical R&D, coupled with a strong presence of contract research organizations and advanced academic centers, drives demand for high-performance reagents and integrated instruments that support translational pipelines. Market participants in this region often prioritize regulatory alignment, vendor transparency, and partnership models that can accelerate clinical translation.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks and funding models vary widely, creating both opportunities and complexity. In these markets, suppliers benefit from localized validation data and collaborative partnerships with regional research consortia. Europe in particular emphasizes reproducibility and quality management systems, while several Middle Eastern and African centers are investing in capacity building and infrastructure modernization. Asia-Pacific is characterized by rapid expansion in life science R&D capability, government-led initiatives to support biotechnology, and a growing manufacturing base. Suppliers operating in Asia-Pacific are increasingly localizing production and offering scalable solutions that cater to a broad range of end users, from emerging academic centers to large domestic biopharma firms. Understanding these regional nuances is essential for prioritizing market entry tactics, distribution strategies, and localized service offerings.

Strategic profiles and capability analysis of leading companies shaping transfection reagents and equipment through R&D, partnerships, and platform expansion

Leading companies in the space are differentiating through a combination of R&D investment, strategic partnerships, and expanding platform capabilities. Some firms are concentrating on reagent chemistry optimization to enhance delivery efficiency and reduce cytotoxicity across challenging cell types, while others are integrating hardware, software, and consumables to deliver turnkey solutions that lower the barrier to adoption. Collaborations between reagent developers and instrument manufacturers are becoming more common, as are partnerships with academic labs and contract research organizations to validate workflows across diverse applications.

Corporate strategies also reflect an emphasis on regulatory readiness and quality systems that support translational use cases. Companies that proactively generate comprehensive validation data and provide robust technical support are establishing credibility with biopharmaceutical customers and CROs. Additionally, several firms are exploring modular business models, combining direct sales with channel partnerships and subscription services for consumables and software. These approaches enhance customer lifetime value and create recurring revenue streams while enabling more predictable supply and service delivery for critical R&D activities.

Actionable recommendations for industry leaders to accelerate adoption, optimize supply chains, and capture value across diverse transfection market segments

Industry leaders should adopt a set of pragmatic actions to accelerate adoption, strengthen supply chains, and capture strategic value across segments. First, invest in creating validated, cross-platform protocols and comprehensive application notes that demonstrate performance across the primary cell types and use cases. This evidence base reduces adoption friction and supports procurement decisions across academic, biopharma, and CRO customers. Second, diversify manufacturing and logistics footprints to mitigate trade and tariff risks while ensuring continuity of supply for critical reagents and instrument components.

Third, pursue strategic alliances with technology partners and end users to co-develop solutions tailored to high-value applications such as gene therapy and complex cell line development. Fourth, enhance commercial models by combining equipment sales with consumable subscriptions and managed services that provide predictable revenue and deeper customer engagement. Finally, strengthen technical service and training offerings to support reproducibility and to facilitate rapid scale-up from discovery to translational stages. Together, these actions will help suppliers align product development and go-to-market execution with evolving customer expectations and regulatory requirements.

Research methodology detailing data sources, stakeholder interviews, primary and secondary research integration, and analytical frameworks ensuring rigor

The research methodology underpinning this analysis integrates primary interviews, secondary data synthesis, and cross-validated expert review to ensure analytical rigor and relevance. Primary research included structured interviews with laboratory directors, procurement managers, R&D scientists, and commercial leaders across a representative set of academic institutions, biopharmaceutical companies, and contract research organizations. These conversations provided direct insight into procurement drivers, performance pain points, and validation priorities.

Secondary research involved a systematic review of peer-reviewed literature, regulatory guidance, patent filings, and technical white papers to contextualize technological trends and to verify product claims. Data triangulation was applied to reconcile divergent inputs and to surface consistent patterns across geographies and end-user types. Analytical frameworks used in the study include value chain mapping, supplier capability assessment, and scenario-based sensitivity analysis to explore the impacts of supply disruption and regulatory change. Throughout, subject matter experts provided iterative review to refine interpretations and to ensure that findings are actionable for decision-makers.

Conclusion synthesizing strategic implications, risk considerations, and priority actions for stakeholders navigating the transfection ecosystem

In conclusion, the transfection reagents and equipment ecosystem is advancing at the intersection of innovation, regulatory expectation, and shifting procurement behaviors. Technological progress in delivery chemistries, automation, and integration with gene editing platforms is expanding the range of tractable applications while raising the bar for reproducibility and quality assurance. At the same time, trade dynamics and evolving regional capabilities are reshaping supply chain strategies and commercial approaches.

Stakeholders should prioritize resilience, validated performance, and customer-centric service models to capture emerging opportunities. For product developers, the imperative is to align R&D investment with the specific needs of diverse cell types and application areas. For end users, building robust vendor qualification and inventory management practices will protect continuity of research. As the field evolves, coordinated partnerships among suppliers, customers, and regulatory bodies will be critical to translate technological potential into clinical and commercial outcomes. The synthesis offered here provides a strategic foundation for informed decision-making and targeted action in this dynamic sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transfection Reagents & Equipment Market, by Product Type

  • 8.1. Equipment
  • 8.2. Reagents

9. Transfection Reagents & Equipment Market, by Cell Type

  • 9.1. Bacterial Cells
  • 9.2. Insect Cells
  • 9.3. Mammalian Cells
  • 9.4. Plant Cells

10. Transfection Reagents & Equipment Market, by Application

  • 10.1. Cell Line Development
  • 10.2. Drug Discovery
  • 10.3. Gene Therapy Research

11. Transfection Reagents & Equipment Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Biopharmaceutical Companies
  • 11.3. Contract Research Organizations

12. Transfection Reagents & Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transfection Reagents & Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transfection Reagents & Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transfection Reagents & Equipment Market

16. China Transfection Reagents & Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Altogen Biosystems
  • 17.7. Applied Biological Materials, Inc.
  • 17.8. Bex Co.,ltd.
  • 17.9. BioVision Inc.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. Cytiva
  • 17.12. GeneCopoeia, Inc.
  • 17.13. Lonza Group AG
  • 17.14. Qiagen N.V.
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BACTERIAL CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PLANT CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GENE THERAPY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA TRANSFECTION REAGENTS & EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)